PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), today announced that a series of positive outcomes from the Company’s ongoing development of its patented anti-cancer compounds have prompted researchers to now undertake their first-ever efficacy studies, an important advancement in the drug development process.
